Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Diagnosis of aplastic anemia, with refractory thrombocytopenia following at least one treatment course of horse or rabbit ATG/cyclosporine.~ 2. Platelet count less than or equal to 30,000/microL~ 3. Age greater than or equal to 12 years old~EXCLUSION CRITERIA:~1. Diagnosis of Fanconi anemia~2. Infection not adequately responding to appropriate therapy~3. Patients with a PNH clone size in neutrophils of greater than or equal to 50%~4. HIV positivity~5. Creatinine \> 2.5~6. Bilirubin \> 2.0~7. SGOT or SGPT \> 5 times the upper limit of normal~8. Hypersensitivity to eltrombopag or its components~9. Female subjects who are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~10. History of malignancy other than localized tumors diagnosed more than one year previously and treated surgically with curative intent (for instance squamous cell or other skin cancers, stage 1 breast cancer, cervical carcinoma in situ, etc)~11. Unable to understand the investigational nature of the study or give informed consent~12. History of congestive heart failure arrhythmia requiring chronic treatment, arterial or venous thrombosis (not excluding line thrombosis) within the last 1 year, or myocardial infarction within 3 months before enrollment~13. ECOG Performance Status of 3 or greater~14. Treatment with horse or rabbit ATG or Campath within 6 months of study entry. Concurrent stable treatment with cyclosporine or G-CSF is permitted.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).